Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma
JAMA Oncology - United States
doi 10.1001/jamaoncol.2019.1179
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2019
Authors
Publisher
American Medical Association (AMA)